Deferred Income Tax Expense (Benefit) in USD of PLAYSTUDIOS, Inc. from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
PLAYSTUDIOS, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and change rate from 2019 to 2024.
  • PLAYSTUDIOS, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2024 was -$134K, a 94% increase year-over-year.
  • PLAYSTUDIOS, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$1.37M, a 111% decline from 2023.
  • PLAYSTUDIOS, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $12.4M.
  • PLAYSTUDIOS, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$7.73M, a 230% decline from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)

PLAYSTUDIOS, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$134K +$2.09M +94% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024
Q1 2023 -$2.23M -$10.2M -128% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q1 2022 $7.95M +$8.06M 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q1 2021 -$110K 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022

PLAYSTUDIOS, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1.37M -$13.8M -111% 01 Jan 2024 31 Dec 2024 10-K 14 Mar 2025
2023 $12.4M +$20.1M 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025
2022 -$7.73M -$5.39M -230% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024
2021 -$2.34M +$1.36M +36.7% 01 Jan 2021 31 Dec 2021 10-K 12 Mar 2024
2020 -$3.7M -$6.05M -258% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2023
2019 $2.35M 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.